{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T07:24:24Z","timestamp":1787124264970,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Pamukkale University Scientific Research Projects Coordination Unit","award":["2020TIPF026, 2020HZDP019, 2020HZDP020 and 2020HZDP022"],"award-info":[{"award-number":["2020TIPF026, 2020HZDP019, 2020HZDP020 and 2020HZDP022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-05031-0","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:34:13Z","timestamp":1781519653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regenerative effects of RKI-1447 on human corneal endothelial cells: a comparative study"],"prefix":"10.1186","volume":"26","author":[{"given":"Hasan Samed","family":"Akkaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine","family":"Kilic-Toprak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayseg\u00fcl","family":"Cort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Parca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Toprak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"5031_CR1","doi-asserted-by":"publisher","first-page":"108462","DOI":"10.1016\/j.exer.2021.108462","volume":"204","author":"PA Faye","year":"2021","unstructured":"Faye PA, Poumeaud F, Chazelas P, et al. Focus on cell therapy to treat corneal endothelial diseases. Exp Eye Res. 2021;204:108462. https:\/\/doi.org\/10.1016\/j.exer.2021.108462.","journal-title":"Exp Eye Res"},{"key":"5031_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.trsl.2022.05.003","volume":"248","author":"H Vercammen","year":"2022","unstructured":"Vercammen H, Miron A, Oellerich S, et al. Corneal endothelial wound healing: understanding the regenerative capacity of the innermost layer of the cornea. Transl Res. 2022;248:111\u201327. https:\/\/doi.org\/10.1016\/j.trsl.2022.05.003.","journal-title":"Transl Res"},{"key":"5031_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/ICU.0000000000000853","volume":"33","author":"EN Wong","year":"2022","unstructured":"Wong EN, Mehta JS. Cell therapy in corneal endothelial disease. Curr Opin Ophthalmol. 2022;33:275\u201381. https:\/\/doi.org\/10.1097\/ICU.0000000000000853.","journal-title":"Curr Opin Ophthalmol"},{"key":"5031_CR4","first-page":"2152","volume":"43","author":"NC Joyce","year":"2002","unstructured":"Joyce NC, Harris DL, Mello DM. Mechanisms of mitotic inhibition in corneal endothelium: contact inhibition and TGF-beta2. Invest Ophthalmol Vis Sci. 2002;43:2152\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5031_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10792-024-02994-1","volume":"44","author":"F Altamirano","year":"2024","unstructured":"Altamirano F, Ortiz-Morales G, O\u2019Connor-Cordova MA, Sanc\u00e9n-Herrera JP, Zavala J, Valdez-Garcia JE. Fuchs endothelial corneal dystrophy: an updated review. Int Ophthalmol. 2024;44:61. https:\/\/doi.org\/10.1007\/s10792-024-02994-1.","journal-title":"Int Ophthalmol"},{"key":"5031_CR6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1136\/bjophthalmol-2020-316149","volume":"105","author":"HS Ong","year":"2021","unstructured":"Ong HS, Ang M, Mehta J. Evolution of therapies for the corneal endothelium: past, present and future approaches. Br J Ophthalmol. 2021;105:454\u201367. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316149.","journal-title":"Br J Ophthalmol"},{"key":"5031_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ajo.2022.09.013","volume":"245","author":"AB Maier","year":"2023","unstructured":"Maier AB, Milek J, Joussen AM, et al. Systematic Review and Meta-analysis: Outcomes After Descemet Membrane Endothelial Keratoplasty Versus Ultrathin Descemet Stripping Automated Endothelial Keratoplasty. Am J Ophthalmol. 2023;245:222\u201332. https:\/\/doi.org\/10.1016\/j.ajo.2022.09.013.","journal-title":"Am J Ophthalmol"},{"key":"5031_CR8","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1016\/j.ophtha.2015.08.017","volume":"122","author":"CY Park","year":"2015","unstructured":"Park CY, Lee JK, Gore PK, et al. Keratoplasty in the United States: A 10-Year Review from 2005 through 2014. Ophthalmology. 2015;122:2432\u201342. https:\/\/doi.org\/10.1016\/j.ophtha.2015.08.017.","journal-title":"Ophthalmology"},{"key":"5031_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamaophthalmol.2015.4776","volume":"134","author":"P Gain","year":"2016","unstructured":"Gain P, Jullienne R, He Z, et al. Global Survey of Corneal Transplantation and Eye Banking. JAMA Ophthalmol. 2016;134:167\u201373. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.4776.","journal-title":"JAMA Ophthalmol"},{"key":"5031_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2217\/rme-2021-0149","volume":"17","author":"M Parekh","year":"2022","unstructured":"Parekh M, Wongvisavavit R, Cubero Cortes ZM, et al. Alternatives to endokeratoplasty: an attempt towards reducing global demand of human donor corneas. Regen Med. 2022;17:461\u201375. https:\/\/doi.org\/10.2217\/rme-2021-0149.","journal-title":"Regen Med"},{"key":"5031_CR11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/ICU.0000000000001050","volume":"35","author":"EH Koo","year":"2024","unstructured":"Koo EH. Current state of endothelial cell therapy. Curr Opin Ophthalmol. 2024;35:304\u20138. https:\/\/doi.org\/10.1097\/ICU.0000000000001050.","journal-title":"Curr Opin Ophthalmol"},{"key":"5031_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/DDDT.S435522","volume":"18","author":"S Futterknecht","year":"2024","unstructured":"Futterknecht S, Chatzimichail E, Gugleta K, Panos GD, Gatzioufas Z. The Role of Rho Kinase Inhibitors in Corneal Diseases. Drug Des Devel Ther. 2024;18:97\u2013108. https:\/\/doi.org\/10.2147\/DDDT.S435522.","journal-title":"Drug Des Devel Ther"},{"key":"5031_CR13","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.3390\/jcm12216736","volume":"12","author":"L Pagano","year":"2023","unstructured":"Pagano L, Lee JW, Posarelli M, Giannaccare G, Kaye S, Borgia A. ROCK Inhibitors in Corneal Diseases and Glaucoma-A Comprehensive Review of These Emerging Drugs. J Clin Med. 2023;12:6736. https:\/\/doi.org\/10.3390\/jcm12216736.","journal-title":"J Clin Med"},{"key":"5031_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/ceo.14224","volume":"51","author":"R Karri","year":"2023","unstructured":"Karri R, Chong EW. ROCK inhibitors in ophthalmology: A critical review of the existing clinical evidence. Clin Exp Ophthalmol. 2023;51:472\u201383. https:\/\/doi.org\/10.1111\/ceo.14224.","journal-title":"Clin Exp Ophthalmol"},{"key":"5031_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ajpath.2012.03.033","volume":"181","author":"N Okumura","year":"2012","unstructured":"Okumura N, Koizumi N, Ueno M, et al. ROCK inhibitor converts corneal endothelial cells into a phenotype capable of regenerating in vivo endothelial tissue. Am J Pathol. 2012;181:268\u201377. https:\/\/doi.org\/10.1016\/j.ajpath.2012.03.033.","journal-title":"Am J Pathol"},{"key":"5031_CR16","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.1167\/iovs.15-17595","volume":"56","author":"N Okumura","year":"2015","unstructured":"Okumura N, Inoue R, Okazaki Y, et al. Effect of the Rho Kinase Inhibitor Y-27632 on Corneal Endothelial Wound Healing. Invest Ophthalmol Vis Sci. 2015;56:6067\u201374. https:\/\/doi.org\/10.1167\/iovs.15-17595.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5031_CR17","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1158\/0008-5472.CAN-12-0954","volume":"72","author":"RA Patel","year":"2012","unstructured":"Patel RA, Forinash KD, Pireddu R, et al. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012;72:5025\u201334. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0954.","journal-title":"Cancer Res"},{"key":"5031_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00417-018-4175-6","volume":"257","author":"Y Dang","year":"2019","unstructured":"Dang Y, Wang C, Shah P, Waxman S, Loewen RT, Loewen NA. RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis. Graefes Arch Clin Exp Ophthalmol. 2019;257:101\u20139. https:\/\/doi.org\/10.1007\/s00417-018-4175-6.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5031_CR19","doi-asserted-by":"publisher","unstructured":"Shin H, Min JK, Kim NR et al. Effects of Y-27632, a rho-associated kinase inhibitor, on human corneal endothelial cells cultured by isolating human corneal endothelial progenitor cells. Korean J Ophthalmol. 2023;37:31\u201341. https:\/\/doi.org\/10.3341\/kjo.2022.0133","DOI":"10.3341\/kjo.2022.0133"},{"key":"5031_CR20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ophtha.2020.09.002","volume":"128","author":"K Numa","year":"2021","unstructured":"Numa K, Imai K, Ueno M, et al. Five-Year Follow-up of First 11 Patients Undergoing Injection of Cultured Corneal Endothelial Cells for Corneal Endothelial Failure. Ophthalmology. 2021;128:504\u201314. https:\/\/doi.org\/10.1016\/j.ophtha.2020.09.002.","journal-title":"Ophthalmology"},{"key":"5031_CR21","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1097\/ICO.0b013e318285475d","volume":"32","author":"N Koizumi","year":"2013","unstructured":"Koizumi N, Okumura N, Ueno M, Nakagawa H, Hamuro J, Kinoshita S. Rho-associated kinase inhibitor eye drop treatment as a possible medical treatment for Fuchs corneal dystrophy. Cornea. 2013;32:1167\u201370. https:\/\/doi.org\/10.1097\/ICO.0b013e318285475d.","journal-title":"Cornea"},{"key":"5031_CR22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/jcp.28965","volume":"235","author":"L Li","year":"2020","unstructured":"Li L, Chen Q, Yu Y, et al. RKI-1447 suppresses colorectal carcinoma cell growth via disrupting cellular bioenergetics and mitochondrial dynamics. J Cell Physiol. 2020;235:254\u201366. https:\/\/doi.org\/10.1002\/jcp.28965.","journal-title":"J Cell Physiol"},{"key":"5031_CR23","doi-asserted-by":"publisher","first-page":"116435","DOI":"10.1016\/j.biopha.2024.116435","volume":"174","author":"H Vercammen","year":"2024","unstructured":"Vercammen H, Ondra M, Kotulova J, et al. Keep on ROCKIn: Repurposed ROCK inhibitors to boost corneal endothelial regeneration. Biomed Pharmacother. 2024;174:116435. https:\/\/doi.org\/10.1016\/j.biopha.2024.116435.","journal-title":"Biomed Pharmacother"},{"key":"5031_CR24","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3390\/cells12091307","volume":"12","author":"GSL Peh","year":"2023","unstructured":"Peh GSL, Bandeira F, Neo D, et al. Effects of Rho-Associated Kinase (Rock) Inhibitors (Alternative to Y-27632) on Primary Human Corneal Endothelial Cells. Cells. 2023;12:1307. https:\/\/doi.org\/10.3390\/cells12091307.","journal-title":"Cells"},{"key":"5031_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1167\/iovs.13-12225","volume":"55","author":"N Okumura","year":"2014","unstructured":"Okumura N, Nakano S, Kay EP, et al. Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing. Invest Ophthalmol Vis Sci. 2014;55:318\u201329. https:\/\/doi.org\/10.1167\/iovs.13-12225.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05031-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:36:26Z","timestamp":1787121386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-05031-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5031"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05031-0","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study was conducted using a commercially available human corneal endothelial primary cell line (Cat# 36081-13-T25, Cellprogen Inc., Torrance, CA, USA). As the cells were obtained from a commercial source and the research involved strictly in vitro experiments on an established cell line, institutional ethics committee approval and informed consent were not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study did not involve human participants, patient data, or any identifiable personal information.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"504"}}